TARGET RESEARCH ARTICLES
-
The Future Is Ancient: Evolution, Metabolics, And AI
We caught up with Hannah Gordon, Ph.D., chief scientific officer of Enveda, to discuss why the future may depend more on decoding nature’s evolutionarily selected chemistry.
-
Beyond Engineered Antibodies: Harnessing The Natural Human Repertoire
We caught up Srikanth Pendyala, MD, CMO of Infinimmune, to discuss the importance of learning directly from the human immune system itself in antibody research.
-
How Rh Incompatibility Endangers Pregnancies And How Rhogam Helped My Family (Part 1 Of 3)
Rh incompatibility can make pregnancy dangerous. Rhogam helped protect my family and stands as a powerful example of unconventional drug discovery.
-
2026 Nucleate Boston Activator Cohort Interview: Ryan Posey & Anusha Manglik — Resilientia Therapeutics
Startup founders of Resilientia Tx discuss protecting cancer patients from radiation side effects, organ-on-a-chip discovery, Nucleate Boston, and early startup challenges.
-
A New De Novo Protein Design Platform For GPCR Drug Discovery
Skape Bio and UW created an AI-driven platform to design miniproteins that modulate GPCRs in living cells, opening new paths for biologic drug discovery.
-
Advancing Spatial Multiomics for Discovery: From Promise to Practice
Spatial multiomics offers extraordinary biological insight, but high costs, tissue bottlenecks, and unclear clinical relevance still limit its reach.
TARGET RESEARCH ARTICLES. APP NOTES, CASE STUDIES. & WHITE PAPERS
-
Well-designed lipid nanoparticles enable safe, efficient delivery. OVA-based models show how formulation choices shape efficacy, safety, and anti-tumor outcomes in melanoma research.
-
Gain mechanistic insights beyond traditional viability assays, revealing nuanced cellular phenotypes and strengthening early drug discovery decisions without sacrificing throughput or efficiency.
-
Structure‑enabled drug discovery revealed a novel, druggable binding site in Artemis, enabling rapid SAR optimization and a ~500‑fold potency improvement against a challenging oncology target.
-
Explore how real-time kinetic analysis reveals how conjugation, linker chemistry, and drug loading influence antibody–antigen interactions, while enabling sensitive detection of anti-drug antibodies.
-
New advances in chemomics, proteome mapping, and modern synthetic methods are redefining how quickly and precisely discovery teams can move from raw data to meaningful clinical momentum.
-
Sensitive digital PCR methods enable confident detection of low‑abundance iPSC markers. Gain insight into how these capabilities support more reliable monitoring and quality assessment.
TARGET RESEARCH SOLUTIONS
-
Macrocycles expand drug discovery into previously inaccessible targets. With validated success and flexible approaches, they provide a powerful path for tackling the most challenging biology.
-
CHO cells have been the workhorse for protein and antibody manufacturing. The major advantages of CHO include robust growth, hardiness in suspension culture, stellar protein production and secretion, and a long track record.
-
HEK293 cells have been the most popular mammalian transient production platform. The primary advantage of HEK293 cells is transfection efficiency.
-
The demand for high-throughput antibodies has exponentially increased over the last couple of years and has rapidly accelerated the antibody screening process.
-
E. coli is often the system of choice for biomanufacturing because of its amenability to genetic manipulation, low production cost, and rapid timelines for bioexpression.
-
Curia provides a wide range of biochemical and cell-based bioassay workflows to support Discovery, Research & Development as well as cGxP therapeutic testing campaigns
-
We deliver custom assay development, screening, potency, and selectivity testing services for the pharmaceutical, biopharmaceutical, and agrochemical industries.
-
Evaluating small and large molecule therapeutics within cellular environments is essential to understanding their efficacy, potency, and safety within a complex biological system.
-
Curia’s expert scientists use advanced technology to produce and analyze high-quality recombinant proteins.
-
Curia’s discovery biology team accelerates your program toward the clinic and commercialization with our best-in-class, customizable solutions.
-
At Curia, our team of expert protein chemists and structural biologists brings the advanced experience and technology needed to support all your structural biology services needs.
-
High‑throughput scNMT‑seq offers a powerful way to map methylation and transcriptional activity. Learn about strategies that cut variability and support dependable multi‑omics datasets.
-
Generate human-relevant data with an Organ-Chip system that combines automation, imaging, and cost efficiency for faster, more confident insights for drug development and complex biological studies.
-
With 12 independent Emulations in one consumable, Chip-Array optimizes workflows and reduces cell requirements—delivering scalable, physiologically relevant models for advanced research.